Bristol Myers Financials
This page shows Bristol Myers (BMYMP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 19 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High gross margins and minimal capital spending keep cash generation resilient even when reported earnings swing sharply.
Reported earnings and cash generation diverged sharply across FY2024 and FY2025: the business posted a-$8.9B net loss in FY2024 while still producing$15.2B of operating cash flow. With net income back to$7.1B in FY2025 but operating cash flow still near$14.2B , the core engine looks steadier than the bottom line, implying the prior-year loss reflected accounting pressure more than a collapse in cash receipts.
Margin compression appears real: gross margin settled at
Leverage still dominates the balance-sheet picture because long-term debt of
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Bristol Myers's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Bristol Myers's revenue declined 0.2% year-over-year, from $48.3B to $48.2B. This contraction results in a growth score of 39/100.
Bristol Myers has a moderate D/E ratio of 2.32. This balance of debt and equity financing earns a leverage score of 55/100.
Bristol Myers's current ratio of 1.26 is below the typical benchmark, resulting in a score of 20/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Bristol Myers converts 26.7% of revenue into free cash flow ($12.8B). This strong cash generation earns a score of 94/100.
Bristol Myers generates a 38.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 29/100. This is up from -54.8% the prior year.
Bristol Myers passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Bristol Myers generates $2.01 in operating cash flow ($14.2B OCF vs $7.1B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Bristol Myers generated $48.2B in revenue in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Bristol Myers reported $7.1B in net income in fiscal year 2025. This represents an increase of 178.8% from the prior year.
Bristol Myers earned $3.46 per diluted share (EPS) in fiscal year 2025. This represents an increase of 178.5% from the prior year.
Cash & Balance Sheet
Bristol Myers generated $12.8B in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 7.9% from the prior year.
Bristol Myers held $10.2B in cash against $42.9B in long-term debt as of fiscal year 2025.
Bristol Myers paid $2.49 per share in dividends in fiscal year 2025. This represents an increase of 2.9% from the prior year.
Bristol Myers had 2.04B shares outstanding in fiscal year 2025. This represents an increase of 0.4% from the prior year.
Margins & Returns
Bristol Myers's gross margin was 71.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.0 percentage points from the prior year.
Bristol Myers's net profit margin was 14.6% in fiscal year 2025, showing the share of revenue converted to profit. This is up 33.2 percentage points from the prior year.
Bristol Myers's ROE was 38.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 93.0 percentage points from the prior year.
Capital Allocation
Bristol Myers invested $10.0B in research and development in fiscal year 2025. This represents a decrease of 10.8% from the prior year.
Bristol Myers spent $0 on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Bristol Myers invested $1.3B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 5.0% from the prior year.
BMYMP Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.5B-8.1% | $12.5B+2.3% | $12.2B-0.4% | $12.3B+9.5% | $11.2B-9.2% | $12.3B+3.8% | $11.9B-2.5% | $12.2B |
| Cost of Revenue | $3.4B-16.5% | $4.1B+19.2% | $3.4B+1.9% | $3.4B+11.2% | $3.0B-37.0% | $4.8B+62.7% | $3.0B-9.5% | $3.3B |
| Gross Profit | $8.1B-4.0% | $8.4B-4.3% | $8.8B-1.2% | $8.9B+8.9% | $8.2B+8.5% | $7.5B-15.7% | $8.9B0.0% | $8.9B |
| R&D Expenses | $2.6B+2.4% | $2.6B+2.3% | $2.5B-2.0% | $2.6B+14.3% | $2.3B-29.3% | $3.2B+34.4% | $2.4B-18.1% | $2.9B |
| SG&A Expenses | $1.6B-25.9% | $2.2B+21.9% | $1.8B+4.4% | $1.7B+8.1% | $1.6B-25.8% | $2.1B+7.7% | $2.0B+2.9% | $1.9B |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $411.0M-4.9% | $432.0M-10.0% | $480.0M-1.0% | $485.0M-1.8% | $494.0M-0.4% | $496.0M-1.8% | $505.0M-3.1% | $521.0M |
| Income Tax | $561.0M+46.1% | $384.0M-58.2% | $919.0M+99.8% | $460.0M-9.6% | $509.0M+414.1% | $99.0M-78.5% | $461.0M+215.8% | -$398.0M |
| Net Income | $2.7B+146.3% | $1.1B-50.6% | $2.2B+68.0% | $1.3B-46.7% | $2.5B+3311.1% | $72.0M-94.1% | $1.2B-27.9% | $1.7B |
| EPS (Diluted) | $1.31 | N/A | $1.08+68.8% | $0.64-46.7% | $1.20 | N/A | $0.60-27.7% | $0.83 |
BMYMP Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $86.5B-4.0% | $90.0B-7.1% | $96.9B+2.3% | $94.7B+2.4% | $92.4B-0.2% | $92.6B-1.1% | $93.7B-1.0% | $94.6B |
| Current Assets | $27.2B-7.4% | $29.4B-17.5% | $35.6B+7.2% | $33.2B+7.9% | $30.8B+3.4% | $29.8B+6.1% | $28.1B+4.4% | $26.9B |
| Cash & Equivalents | $9.6B-6.2% | $10.2B-35.1% | $15.7B+24.8% | $12.6B+15.9% | $10.9B+5.1% | $10.3B+31.1% | $7.9B+25.4% | $6.3B |
| Inventory | $2.8B+2.5% | $2.7B-2.5% | $2.8B+0.8% | $2.7B+2.7% | $2.7B+4.3% | $2.6B-23.3% | $3.3B+8.3% | $3.1B |
| Accounts Receivable | $7.9B-17.2% | $9.6B-0.3% | $9.6B-0.9% | $9.7B+7.1% | $9.1B+0.6% | $9.0B-3.3% | $9.3B-4.4% | $9.7B |
| Goodwill | $21.7B-0.1% | $21.8B0.0% | $21.7B-0.1% | $21.8B+0.2% | $21.7B+0.1% | $21.7B-0.1% | $21.8B+0.1% | $21.7B |
| Total Liabilities | $66.4B-7.2% | $71.5B-8.6% | $78.3B+1.4% | $77.2B+2.9% | $75.0B-1.6% | $76.2B-0.3% | $76.5B-1.4% | $77.6B |
| Current Liabilities | $19.2B-18.2% | $23.4B-16.8% | $28.1B+2.2% | $27.5B+14.4% | $24.1B+1.2% | $23.8B+5.0% | $22.6B-2.7% | $23.3B |
| Long-Term Debt | $42.2B-1.6% | $42.9B-3.6% | $44.5B0.0% | $44.5B-3.7% | $46.2B-3.0% | $47.6B-2.2% | $48.7B-0.4% | $48.9B |
| Total Equity | $20.1B+8.6% | $18.5B-0.4% | $18.6B+6.4% | $17.4B+0.3% | $17.4B+6.5% | $16.3B-4.7% | $17.1B+0.7% | $17.0B |
| Retained Earnings | $18.3B+8.2% | $16.9B-1.2% | $17.1B+5.8% | $16.2B+0.3% | $16.1B+8.0% | $14.9B-7.4% | $16.1B0.0% | $16.1B |
BMYMP Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.1B-44.1% | $2.0B-68.7% | $6.3B+61.1% | $3.9B+100.5% | $2.0B-56.0% | $4.4B-20.6% | $5.6B+140.4% | $2.3B |
| Capital Expenditures | $347.0M-6.2% | $370.0M+15.6% | $320.0M-11.4% | $361.0M+38.8% | $260.0M-31.2% | $378.0M+16.7% | $324.0M+23.7% | $262.0M |
| Free Cash Flow | $757.0M-52.8% | $1.6B-73.2% | $6.0B+68.5% | $3.6B+109.9% | $1.7B-58.3% | $4.1B-22.9% | $5.3B+155.2% | $2.1B |
| Investing Cash Flow | -$131.0M+91.0% | -$1.5B+14.3% | -$1.7B-259.8% | -$473.0M+5.2% | -$499.0M-154.6% | -$196.0M+10.5% | -$219.0M+83.4% | -$1.3B |
| Financing Cash Flow | -$1.6B+74.1% | -$6.0B-304.6% | -$1.5B+18.8% | -$1.8B-84.9% | -$993.0M+39.5% | -$1.6B+57.4% | -$3.9B+4.3% | -$4.0B |
| Dividends Paid | $1.3B+1.7% | $1.3B-0.1% | $1.3B+0.1% | $1.3B+0.3% | $1.3B+3.3% | $1.2B+0.2% | $1.2B-0.1% | $1.2B |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 |
BMYMP Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.2%+3.0pp | 67.2%-4.6pp | 71.9%-0.6pp | 72.5%-0.4pp | 72.9%+11.9pp | 61.0%-14.1pp | 75.1%+1.9pp | 73.2% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | 23.3%+14.6pp | 8.7%-9.3pp | 18.0%+7.3pp | 10.7%-11.2pp | 21.9%+21.3pp | 0.6%-9.6pp | 10.2%-3.6pp | 13.8% |
| Return on Equity | 13.3%+7.5pp | 5.9%-6.0pp | 11.9%+4.3pp | 7.5%-6.6pp | 14.1%+13.7pp | 0.4%-6.6pp | 7.1%-2.8pp | 9.9% |
| Return on Assets | 3.1%+1.9pp | 1.2%-1.1pp | 2.3%+0.9pp | 1.4%-1.3pp | 2.7%+2.6pp | 0.1%-1.2pp | 1.3%-0.5pp | 1.8% |
| Current Ratio | 1.42+0.2 | 1.26-0.0 | 1.27+0.1 | 1.21-0.1 | 1.28+0.0 | 1.25+0.0 | 1.24+0.1 | 1.16 |
| Debt-to-Equity | 2.10-0.2 | 2.32-0.1 | 2.40-0.2 | 2.55-0.1 | 2.65-0.3 | 2.91+0.1 | 2.84-0.0 | 2.87 |
| FCF Margin | 6.6%-6.2pp | 12.8%-36.2pp | 49.0%+20.0pp | 29.0%+13.9pp | 15.1%-17.8pp | 32.9%-11.4pp | 44.3%+27.4pp | 16.9% |
Frequently Asked Questions
What is Bristol Myers's annual revenue?
Bristol Myers (BMYMP) reported $48.2B in total revenue for fiscal year 2025. This represents a -0.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Bristol Myers's revenue growing?
Bristol Myers (BMYMP) revenue declined by 0.2% year-over-year, from $48.3B to $48.2B in fiscal year 2025.
Is Bristol Myers profitable?
Yes, Bristol Myers (BMYMP) reported a net income of $7.1B in fiscal year 2025, with a net profit margin of 14.6%.
How much debt does Bristol Myers have?
As of fiscal year 2025, Bristol Myers (BMYMP) had $10.2B in cash and equivalents against $42.9B in long-term debt.
What is Bristol Myers's gross margin?
Bristol Myers (BMYMP) had a gross margin of 71.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Bristol Myers's net profit margin?
Bristol Myers (BMYMP) had a net profit margin of 14.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Bristol Myers pay dividends?
Yes, Bristol Myers (BMYMP) paid $2.49 per share in dividends during fiscal year 2025.
What is Bristol Myers's return on equity (ROE)?
Bristol Myers (BMYMP) has a return on equity of 38.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Bristol Myers's free cash flow?
Bristol Myers (BMYMP) generated $12.8B in free cash flow during fiscal year 2025. This represents a -7.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Bristol Myers's operating cash flow?
Bristol Myers (BMYMP) generated $14.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Bristol Myers's total assets?
Bristol Myers (BMYMP) had $90.0B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Bristol Myers's capital expenditures?
Bristol Myers (BMYMP) invested $1.3B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Bristol Myers spend on research and development?
Bristol Myers (BMYMP) invested $10.0B in research and development during fiscal year 2025.
What is Bristol Myers's current ratio?
Bristol Myers (BMYMP) had a current ratio of 1.26 as of fiscal year 2025, which is considered adequate.
What is Bristol Myers's debt-to-equity ratio?
Bristol Myers (BMYMP) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Bristol Myers's return on assets (ROA)?
Bristol Myers (BMYMP) had a return on assets of 7.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Bristol Myers's Piotroski F-Score?
Bristol Myers (BMYMP) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bristol Myers's earnings high quality?
Bristol Myers (BMYMP) has an earnings quality ratio of 2.01x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Bristol Myers?
Bristol Myers (BMYMP) scores 40 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.